

## Polio this week as of 15 September 2020

Country or territory <sup>3</sup>	Wild virus type 1 conf					
	Full year total					01
	2015	2016	2017	2018	2019	20
Pakistan	54	20	8	12	147	6
Afghanistan	20	13	14	21	29	1
Nigeria <sup>3</sup>	0	4	0	0	0	0
Iran	0	0	0	0	0	0
<b>Total (Type1)</b>	<b>74</b>	<b>37</b>	<b>22</b>	<b>33</b>	<b>176</b>	<b>7</b>
<b>Tot. in endemic countries</b>	74	37	22	33	176	7
<b>Tot. in non-end countries</b>	0	0	0	0	0	0
<b>No. of countries (infected)</b>	2	3	2	2	2	2
<b>No. of countries (endemic)</b>	3	2 <sup>3</sup>	2 <sup>3</sup>	3	3	3
<b>Total Female</b>	30	13	7	18	72	3
<b>Total Male</b>	44	24	15	15	104	4

### Headlines:

- The Polio Oversight Board (POB) held its second meeting of the year virtually to discuss the programme's financial requirements for 2021, to receive an update on the recommendations of the GPEI Governance Review and to consider a proposal to develop a new polio programme strategy. **Read more** on the meeting.
- When the COVID-19 pandemic struck, the acute challenges it posed to both

---

polio and immunization activities presented an unprecedented opportunity to coordinate and reimagine collaboration. Given the new context, the focus of the work shifted to develop an interim Programme of Work for Integrated Actions in the context of COVID-19 (iPOW). **The draft iPOW** summarizes the current level of integration between GPEI and EPI and, more importantly, identifies critical actions across key priority areas of work to drive synergies and materialize efficiency gains by building on initiatives accelerated by COVID-19 to ensure a successful resumption of all immunization activities. iPOW is open for stakeholder consultation until October 1st, 2020.

- The GPEI established an nOPV2 Working Group to manage and coordinate the rapid and effective rollout of nOPV2. The group includes representatives from each of the GPEI partner organizations and focuses on research, regulatory, supply, communications, policy, and implementation readiness activities. Take a look at an **updated information sheet** detailing the structures and linkages of the Working Group.

#### **Afghanistan:**

- **Two wild poliovirus type 1 (WPV1) cases were reported; one each in Khost and Paktika provinces.** There are 46 WPV1 cases reported in 2020 so far while the total number of cases reported in 2019 remains 29.
- One wild poliovirus type 1 (WPV1) positive environmental sample was reported in Hirat province.
- Nine cVDPV2 cases were reported; one each in Hilmand, Jawzjan, Kabul, Kandahar, Khost, Laghman and Nimroz provinces, and two in Nangarhar province. There are 78 cVDPV2 cases reported in 2020 so far.

#### **Pakistan:**

- **Two wild poliovirus type 1 (WPV1) cases were reported;** one each in Balochistan and Sindh province. There are 70 WPV1 cases reported in 2020 so

---

far while the total number of cases reported in 2019 cases remains 147.

- Eight WPV1 positive environmental samples were reported; five in Balochistan, one in Islamabad and two in Punjab.
- Seven cVDPV2 cases were reported; five in Punjab and two in Sindh. There are 59 cVDPV2 cases reported in 2020 so far while the 2019 case count remains 22.

**Officially reported WPV cases as of 15 Sept**

**Total global WPV1 cases in 2020: 116** (compared with 78 for the same period in 2019)

**Total global WPV1 cases in 2019: 176**

**Circulating vaccine-derived poliovirus (cVDPV) cases**

**Total global cVDPV cases in 2020: 392** (compared with 85 for the same period in 2019)

**Total global cVDPV cases in 2019: 369**